Protein-losing Enteropathy Complicated with Primary Intestinal Follicular Lymphoma

Tomoki Minemura, Shohei Kikuchi, Hiroshi Mihara, Yusuke Kamihara, Akinori Wada, Mayo Fuchino, Sohachi Nanjo, Akira Noguchi, Takashi Minamisaka, Jun Murakami, Ichiro Yasuda, and Tsutomu Sato

Abstract:
Protein-losing enteropathy (PLE) is a rare syndrome characterized by hypoproteinemia due to gastrointestinal (GI) protein loss. Primary intestinal follicular lymphoma (PIFL), a specific variant of follicular lymphoma with essential only GI involvement, has not been reported as an etiology of PLE. We herein report a case of PLE complicated with PIFL that was successfully treated with rituximab, resulting in rapid improvement of PLE and a complete response of PIFL. Macroscopic findings of ulcerative lesions with diffuse involvement, which were precisely described by capsule and double-balloon enteroscopy at the diagnosis, also improved following the treatment. This case provides a clue suggesting factors that promote PLE in PIFL.

Key words: protein-losing enteropathy, primary intestinal follicular lymphoma, rituximab

(Intern Med 61: 2051-2055, 2022)
(DOI: 10.2169/internalmedicine.8261-21)

Introduction
Protein-losing enteropathy (PLE) is a rare syndrome characterized by hypoproteinemia due to gastrointestinal (GI) protein loss, which results in edema, ascites, and pleural effusion (1). Various disorders triggering gastrointestinal erosion, increased central venous pressure, or mesenteric lymphatic obstruction can play a role in the etiology of PLE, including lymphoma.

Duodenal-type follicular lymphoma (D-FL), a synonym for primary intestinal follicular lymphoma (PIFL) and previously referred to as primary GI follicular lymphoma (GI-FL), is a new designation for a specific variant of follicular lymphoma (FL) with clinical and biological features distinct from those of systemic nodal FL, according to the Revised 4th edition of the World Health Organization (WHO) classification (2). Although GI tract involvement is relatively common, accounting for 30% to 40% of primary extra-nodal lymphoma, GI-FL is reportedly quite rare, accounting for 1.0% to 3.6% of GI-NHL (3) and not reported with PLE. Among patients with FL, only two cases with PLE have been reported (4, 5), and both showed mesenteric and paraaortic lymphadenopathy, suggesting mesenteric lymphatic obstruction as a major cause of PLE. However, while GI involvement is an essential component of PIFL, PLE is a rare complication of PIFL.

We herein report a case of PLE complicated with PIFL and treated with rituximab monotherapy, which resulted in rapid improvement of PLE and a complete response of PIFL.

Case Report
A 72-year-old man was referred to the hematology department with a diagnosis of duodenal FL (Grade 1-2), as revealed by esophagastroduodenoscopy during a medical checkup. Map-like erosion surrounded by tiny whitish nodules in the mucosa was observed in the second portion of the duodenum (Fig. 1A). Pathological findings were compat-

1Department of Hematology, Toyama University Hospital, Japan, 2Center for Medical Residency Training, Toyama University Hospital, Japan, 3Third Department of Internal Medicine, Toyama University Hospital, Japan, 4Department of Diagnostic Pathology, Toyama University Hospital, Japan and 5Division of Transfusion Medicine and Cell Therapy, Toyama University Hospital, Japan

Received: July 1, 2021; Accepted: October 14, 2021; Advance Publication by J-STAGE: November 27, 2021
Correspondence to Dr. Shohei Kikuchi, skikuchi@med.u-toyama.ac.jp
A physical examination revealed edema of the lower legs, and a laboratory examination showed hypoproteinemia and hypoalbuminemia, in addition to iron deficiency anemia (IDA) (Table). Enhanced computed tomography showed a few small mesenteric lymphadenopathies with a long diameter <15 mm but no other nodal or extra-nodal involvement (Fig. 2A). 18-fluorodeoxyglucose positron emission tomography (FDG-PET) showed an increased uptake of FDG [maximum standardized uptake value (SUV\textsubscript{max}): 8.91] in the second and third portion of the duodenum and jejunum (Fig. 2B). Capsule enteroscopy (CE) and double-balloon enteroscopy (DBE) showed near-circumferential tiny whitish nodules with skipped low foveation, erosions, and ulcers at the jejunum and ileum, suggesting diffuse lymphoma involving the small intestine and microscopic GI bleeding leading to IDA (Fig. 3A, B). The histological diagnosis of FL in the ileum was confirmed by DBE (Fig. 3C). The lymphatic ducts were not obviously dilated by D2-40 staining, suggesting that lymphatic obstruction was unlikely as an etiology of PLE (Fig. 3C).

Technetium-99 m-human serum albumin (Tc-99 m-HSA) scintigraphy showed diffuse exudation of labeled albumin from the abdominal cavity at 4 hours after injection and movement to the colon at 24 hours after injection, directly demonstrating protein loss from the GI tract (Fig. 3D). PLE due to PIFL was finally diagnosed.

We diagnosed the patient with intestinal FL of stage I (6). For clinical improvement of PLE and IDA, weekly rituximab monotherapy was administered. After initiation of rituximab monotherapy, the serum protein and albumin levels were rapidly increased and finally normalized (Fig. 4). Lower leg edema and body weight gain were also relieved.
IDA also recovered and never relapsed following rituximab monotherapy. Esophagogastroduodenoscopy and CE performed after six cycles of rituximab showed endoscopic improvement with the disappearance of mucosal whitish nodules and ulcers on whole intestinal lesions (Fig. 5A, B).

DBE after completion of one month of eight cycles rituximab monotherapy showed no endoscopic evidence of FL in the intestine (Fig. 5C). Pathological complete response (CR) was confirmed by a random biopsy of the small intestine. Tc-99 m-HSA scintigraphy showed no exudation of labeled

---

**Table. Laboratory Data on Admission.**

| Periphreral blood | Biochemistry |
|-------------------|--------------|
| WBC 4.590 μL      | TP 3.9 g/dL  |
| Neut. 58.8 %      | Alb 2.1 g/dL |
| Lymph. 31.4 %     | T-Bil 0.4 mg/dL |
| Mono. 7.4 %       | D-Bil 0.1 mg/dL |
| Eosino. 1.7 %     | AMY 57 U/L   |
| Baso. 0.7 %       | AST 19 U/L   |
| RBC 421 ×10^12/μL | ALT 12 U/L  |
| Hb 10.3 g/dL      | LDH 186 U/L |
| MCV 79.1 fl       | ALP 159 U/L |
| MCH 24.5 pg       | γ-GTP 10 U/L |
| MCHC 30.9 g/dL    | ChE 86 U/L |
| Plt 30.0 ×10^12/μL| BUN 18.7 mg/dL |
|                  | CRE 0.76 mg/dL |
|                  | UA 5.6 mg/dL |
|                  | Glu 170 mg/dL |
|                  | TG 76 mg/dL |
|                  | T-CHO 156 mg/dL |
|                  | Na 145 mEq/L |
|                  | K 4.3 mEq/L |
|                  | Cl 108 mEq/L |
|                  | Ca 7.4 mg/dL |
|                  | IP 3.6 mg/dL |
|                  | IgG 425 mg/dL |
|                  | IgA 78 mg/dL |
|                  | IgM 41 mg/dL |
|                  | Protein (+/-) |
|                  | Ocult blood (-) |

**Figure 2.** Small mesenteric lymphadenopathy on enhanced computed tomography (A). The intense uptake of 18-fluorodeoxyglucose (FDG) in the second and third portion of the duodenum and jejunum at the initial diagnosis on FDG-PET in maximum intensity projection mode (MIP) (B).
Figure 3. Capsule enteroscopy (A) and double-balloon enteroscopy (B) at the diagnosis. Erosions and ulcers (white arrows) were surrounded by tiny whitish nodules (yellow arrows). Histopathology of the ileum: immunohistochemical staining showing Hematoxylin and Eosin staining (magnification, ×40 and ×400) and D2-40 staining (×100). D2-40 is expressed in lymphatic endothelial cells (black arrows) and follicular dendritic cells (C). Technetium-99m-human serum albumin scintigraphy at the diagnosis (D). Labeled albumin was observed diffusely exuding at 4 hours after injection and moving to the colon at 24 hours after injection (black arrows).

Figure 4. Clinical course with serum total protein and albumin levels.

Discussion

Accurate estimates of the frequency of PLE in PIFL are not available. A literature review by Yamamoto et al. found hypoalbuminemia was present in only 2 of 150 GI-FL cases (1.3%) (3). In both cases, PLE was not definitively diagnosed by Tc-99 m-HSA scintigraphy or alpha-1 antitripsin clearance (7, 8). Regarding FL, only two cases with PLE have been reported (4, 5). One case had duodenal involvement diagnosed by a biopsy, but mesenteric and paraaortic lymphadenopathy were also observed, and abnormal findings of the GI mucosa were not observed (4). The other was a systemic nodal FL case without GI involvement, caused by mesenteric lymphatic obstruction due to mesenteric and paraaortic lymphadenopathy (5). Thus, our report is the first case of PLE accompanied by PIFL diagnosed both endoscopically and histologically.

In a study of 125 PIFL cases, the most commonly involved lesion site was the duodenal second portion (81%), followed by the jejunum (40%), and 85% of cases with duodenal second portion involvement also had jejunal or ileal involvement (9). Simple involvement of the small intestine is not considered to be a promoting factor for PLE. With respect to macroscopic findings, ulcerative lesions are reported in only 5% of cases, and diffuse involvement is also rare (2%), with the most common macroscopic type being multiple nodules and polyoid lesions (92%) (10). The ulcerative lesion with diffuse involvement in our case was an atypical finding for PIFL and was hypothesized to be a promoting factor triggering PLE in PIFL. Indeed, one GI-FL case with hypoalbuminemia showed IDA, suggesting microscopic gastrointestinal bleeding from an intestinal ulcer or erosion (7), and the other showed diffuse involvement and ulceration (8).

DBE is superior to CT and FDG-PET for diagnosing PIFL (11). Given the high incidence of jejunal or ileal involvement, an evaluation of the whole small intestine by CE and/or DBE should be considered essential for elucidating the relationship between clinical features, such as PLE, and macroscopic findings as well as the area of involvement.

In cases of symptomatic PIFL such as PLE, rituximab monotherapy is a reasonable choice for attaining symptomatic improvement and circumventing potential adverse events of multi-agent chemotherapies, such as rituximab-based bendamustine or CHOP. PIFL is considered to have
an excellent long-term survival with a low risk of progression to disseminated nodal disease, even with the watch-and-wait approach (2). PIFL has shown high chemosensitivity to rituximab monotherapy or rituximab-based combination chemotherapy, such as R-CHOP or R-bendamustine. Schmatz et al. reported an 80% CR rate (n=5) following rituximab monotherapy for PIFL (12). Takata et al. also reported a 5-year overall survival of 92% for rituximab monotherapy, compared with 97% for R-CHOP or R-CHOP-like treatment (9).

In conclusion, PLE is a very rare complication of PIFL. The precise evaluation of macroscopic abnormalities and area of involvement within the entire small intestine by CE and DBE is useful for elucidating the endoscopic features. For the treatment of symptomatic PIFL, rituximab monotherapy may be a promising option, resulting in a sufficient clinical response and acceptable tolerability.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement
We are grateful to Dr. Shigeharu Miwa of Takaoka City Hospital for generously providing us pathological images of a duodenal lesion.

References
1. Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol 105: 43-49, 2010.
2. Swerdlow SHCE, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC, Lyon, 2017: 276-277.
3. Yamamoto S, Nakase H, Yamashita K, et al. Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol 45: 370-388, 2010.
4. Cashen AF, Rubin DC, Bartlett NL. Protein losing enteropathy associated with follicular lymphoma of the small bowel. Am J Clin Oncol 32: 222-223, 2009.
5. Kaneko H, Yamashita M, Ohshiro M, et al. Protein-losing enteropathy in a case of nodal follicular lymphoma without a gastrointestinal mucosal lesion. Intern Med 47: 2171-2173, 2008.
6. Rohatiner A, d’Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5: 397-400, 1994.
7. Ahmed S, Singh A, Krauss J, Wenzt T, Gunaratnam NT. Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody. Am J Clin Oncol 26: 408-410, 2003.
8. Peters JH, Rondonotti E, Weijmer EC, Mulder CJ, Jacobs MA. Lymphomatous polyposis of the small intestine. Gastrointest Endosc 67: 763-765, 2008.
9. Takata K, Okada H, Ohmiya N, et al. Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: a multicenter, retrospective analysis in Japan. Cancer Sci 102: 1532-1536, 2011.
10. Ng HJ, Schmigylski R, Nale K, Collins P. Primary intestinal follicular lymphoma presenting as multiple lymphomatous polyposis. BMJ Case Rep 13: e238626, 2020.
11. Higuchi N, Sumida Y, Nakanura K, et al. Impact of double-balloon endoscopy on the diagnosis of jejunoileal involvement in primary intestinal follicular lymphomas: a case series. Endoscopy 41: 175-178, 2009.
12. Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 29: 1445-1451, 2011.